Bausch + Lomb Corporation (BLCO) is a publicly traded Healthcare sector company. As of October 12, 2026, BLCO trades at $16.99 with a market cap of $6.18B and a P/E ratio of -35.72. BLCO moved -1.79% today. Year to date, BLCO is +1.29%; over the trailing twelve months it is +19.97%. Its 52-week range spans $10.45 to $18.92. Analyst consensus is buy with an average price target of $20.60. Rallies surfaces BLCO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief: Bausch + Lomb CEO Brent Saunders will depart by mutual agreement with the board, and Chairman Thomas Appio will become interim chief immediately. The company and Bausch Health expect to raise their 2026 adjusted EBITDA forecasts after preliminary third-quarter results.
| Metric | Value |
|---|---|
| Price | $16.99 |
| Market Cap | $6.18B |
| P/E Ratio | -35.72 |
| EPS | $-0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.92 |
| 52-Week Low | $10.45 |
| Volume | 2.60K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.32B |
| Net Income | $-163.00M |
| Gross Margin | 0.00% |
12 analysts cover BLCO: 0 strong buy, 6 buy, 5 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.60.